A Study of JR-171 in Patients With Mucopolysaccharidosis I
NCT04227600
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Mucopolysaccharidosis I
Interventions
DRUG:
JR-171 (lepunafusp alfa)
Sponsor
JCR Pharmaceuticals Co., Ltd.